KLY.V - Kalytera Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD

Kalytera Therapeutics, Inc.

4040 Civic Center Drive
Suite 200
San Rafael, CA 94903
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert Farrell J.D.CEO, Pres & Director353kN/AN/A
Ms. Victoria Diana RudmanInterim CFO, Treasurer & Sec.53kN/A1968
Mr. Seth YakatanCo-FounderN/AN/A1970
Dr. Stuart L. Silverman M.D., FACP, FACRCo-Chair of Scientific Advisory Board and VP of Medical AffairsN/AN/A1947
Dr. Sari Prutchi-Sagiv Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Kalytera Therapeutics, Inc. a clinical-stage specialty pharmaceutical company, develops cannabidiol medicines for the treatment of serious and life threatening human diseases. The company is developing cannabidiol formulations to prevent and treat acute graft versus host diseases. The company is also developing K-1032, a prodrug for the treatment of chronic inflammatory skin diseases, such as acne vulgaris; K-1012, a prodrug for the treatment of adult respiratory distress syndrome; K-1022, a prodrug to treat ulcerative colitis; and K-1052, a prodrug for the treatment of sepsis-induced acute renal failure and traumatic brain injury. Kalytera Therapeutics, Inc. was founded in 2014 and is headquartered in San Rafael, California.

Corporate Governance

Kalytera Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.